Induced Pluripotent Stem Cells for Treatment of Alzheimer's and Parkinson's Diseases

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Feb 25

PMID 35203418

Authors

David A Yefroyev

Sha Jin

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative diseases are a group of debilitating pathologies in which neuronal tissue dies due to the buildup of neurotoxic plaques, resulting in detrimental effects on cognitive ability, motor control, and everyday function. Stem cell technology offers promise in addressing this problem on multiple fronts, but the conventional sourcing of pluripotent stem cells involves harvesting from aborted embryonic tissue, which comes with strong ethical and practical concerns. The keystone discovery of induced pluripotent stem cell (iPSC) technology provides an alternative and endless source, circumventing the unfavorable issues with embryonic stem cells, and yielding fundamental advantages. This review highlights iPSC technology, the pathophysiology of two major neurodegenerative diseases, Alzheimer's and Parkinson's, and then illustrates current state-of-the-art approaches towards the treatment of the diseases using iPSCs. The technologies discussed in the review emphasize in vitro therapeutic neural cell and organoid development for disease treatment, pathological modeling of neurodegenerative diseases, and 3D bioprinting as it applies to both.

Citing Articles

Induced Pluripotent Stem Cells and CRISPR-Cas9 Innovations for Treating Alpha-1 Antitrypsin Deficiency and Glycogen Storage Diseases.

Walsh C, Jin S Cells. 2024; 13(12.

PMID: 38920680 PMC: 11201389. DOI: 10.3390/cells13121052.

Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders.

Cohen J, Mathew A, Dourvetakis K, Sanchez-Guerrero E, Pangeni R, Gurusamy N Cells. 2024; 13(6.

PMID: 38534355 PMC: 10969521. DOI: 10.3390/cells13060511.

Mitochondrial Complex I and β-Amyloid Peptide Interplay in Alzheimer's Disease: A Critical Review of New and Old Little Regarded Findings.

Atlante A, Valenti D Int J Mol Sci. 2023; 24(21).

PMID: 37958934 PMC: 10650435. DOI: 10.3390/ijms242115951.

Oxygenated Scaffolds for Pancreatic Endocrine Differentiation from Induced Pluripotent Stem Cells.

Huang H, Karanth S, Guan Y, Freeman S, Soron R, Godovich D Adv Healthc Mater. 2023; 13(3):e2302275.

PMID: 37885129 PMC: 11578060. DOI: 10.1002/adhm.202302275.

Ethical Aspects of Human Induced Pluripotent Stem Cells and Alzheimer's Disease: Potentials and Challenges of a Seemingly Harmless Method.

Kropf M J Alzheimers Dis Rep. 2023; 7(1):993-1006.

PMID: 37849627 PMC: 10578332. DOI: 10.3233/ADR-230018.

References

Drozdzik M, Bialecka M, Kurzawski M . Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions. Curr Genomics. 2014; 14(8):568-77. PMC: 3924251. DOI: 10.2174/1389202914666131210212521. View

Yi H, Jeong Y, Kim Y, Choi Y, Moon H, Park S . A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy. Nat Biomed Eng. 2019; 3(7):509-519. DOI: 10.1038/s41551-019-0363-x. View

Choi J, Lee S, Mallard W, Clement K, Tagliazucchi G, Lim H . A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. Nat Biotechnol. 2015; 33(11):1173-81. PMC: 4847940. DOI: 10.1038/nbt.3388. View

Freeman S, Ramos R, Chando P, Zhou L, Reeser K, Jin S . A bioink blend for rotary 3D bioprinting tissue engineered small-diameter vascular constructs. Acta Biomater. 2019; 95:152-164. DOI: 10.1016/j.actbio.2019.06.052. View

Freed C, Greene P, Breeze R, Tsai W, DuMouchel W, Kao R . Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001; 344(10):710-9. DOI: 10.1056/NEJM200103083441002. View

Hu B, Weick J, Yu J, Ma L, Zhang X, Thomson J . Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A. 2010; 107(9):4335-40. PMC: 2840097. DOI: 10.1073/pnas.0910012107. View

Ford E, Pearlman J, Ruan T, Manion J, Waller M, Neely G . Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges. Cells. 2020; 9(11). PMC: 7699962. DOI: 10.3390/cells9112517. View

Mammana S, Fagone P, Cavalli E, Basile M, Petralia M, Nicoletti F . The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. Int J Mol Sci. 2018; 19(3). PMC: 5877692. DOI: 10.3390/ijms19030831. View

Schwartz S, Regillo C, Lam B, Eliott D, Rosenfeld P, Gregori N . Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2014; 385(9967):509-16. DOI: 10.1016/S0140-6736(14)61376-3. View

10.

Kim H, Cho K, Jang H, Lee N, Jung Y, Kim J . Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. Alzheimers Res Ther. 2021; 13(1):154. PMC: 8439008. DOI: 10.1186/s13195-021-00897-2. View

11.

Kumar S, Er P, Lawlor K, Motazedian A, Scurr M, Ghobrial I . Kidney micro-organoids in suspension culture as a scalable source of human pluripotent stem cell-derived kidney cells. Development. 2019; 146(5). PMC: 6432662. DOI: 10.1242/dev.172361. View

12.

Schwartz S, Hubschman J, Heilwell G, Franco-Cardenas V, Pan C, Ostrick R . Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012; 379(9817):713-20. DOI: 10.1016/S0140-6736(12)60028-2. View

13.

De Beaumont L, Pelleieux S, Lamarre-Theroux L, Dea D, Poirier J . Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. J Alzheimers Dis. 2016; 54(3):913-922. DOI: 10.3233/JAD-160373. View

14.

Dugger B, Dickson D . Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017; 9(7). PMC: 5495060. DOI: 10.1101/cshperspect.a028035. View

15.

Wang R, Reddy P . Role of Glutamate and NMDA Receptors in Alzheimer's Disease. J Alzheimers Dis. 2016; 57(4):1041-1048. PMC: 5791143. DOI: 10.3233/JAD-160763. View

16.

Warren D, Tomaskovic-Crook E, Wallace G, Crook J . Engineering human neural tissue analogs by 3D bioprinting and electrostimulation. APL Bioeng. 2021; 5(2):020901. PMC: 8019355. DOI: 10.1063/5.0032196. View

17.

Li L, Lin H, Hua P, Yan L, Dong H, Li T . Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease. Front Neurol. 2020; 11:520934. PMC: 7673431. DOI: 10.3389/fneur.2020.520934. View

18.

Hallett P, Deleidi M, Astradsson A, Smith G, Cooper O, Osborn T . Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 2015; 16(3):269-74. PMC: 4462124. DOI: 10.1016/j.stem.2015.01.018. View

19.

Kapr J, Petersilie L, Distler T, Lauria I, Bendt F, Sauter C . Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Produce Distinct Neural 3D In Vitro Models Depending on Alginate/Gellan Gum/Laminin Hydrogel Blend Properties. Adv Healthc Mater. 2021; 10(16):e2100131. PMC: 11468953. DOI: 10.1002/adhm.202100131. View

20.

Wolf D, Morey R, Kang E, Ma H, Hayama T, Laurent L . Concise Review: Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer: A Horse in the Race?. Stem Cells. 2016; 35(1):26-34. DOI: 10.1002/stem.2496. View